Quest Partners LLC Grows Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

Quest Partners LLC grew its position in Celcuity Inc. (NASDAQ:CELC) by 227.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,962 shares of the company’s stock after buying an additional 13,174 shares during the period. Quest Partners LLC owned 0.05% of Celcuity worth $283,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELC. Values First Advisors Inc. acquired a new stake in Celcuity in the third quarter valued at approximately $86,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Celcuity by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 73,026 shares of the company’s stock valued at $1,089,000 after purchasing an additional 18,809 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Celcuity in the 3rd quarter worth $33,000. SG Americas Securities LLC purchased a new position in Celcuity during the 3rd quarter worth $119,000. Finally, Point72 Asset Management L.P. acquired a new position in Celcuity during the 2nd quarter valued at about $951,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $13.90 on Tuesday. The company has a 50 day simple moving average of $14.90 and a two-hundred day simple moving average of $15.86. The stock has a market cap of $516.11 million, a price-to-earnings ratio of -5.33 and a beta of 0.76. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 12 month low of $11.51 and a 12 month high of $22.19.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CELC. Stifel Nicolaus raised their price target on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Celcuity has an average rating of “Buy” and a consensus target price of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.